IL1A and Alzheimer disease: However, two Phase II trials on Bermekimab, an anti-IL-1αAb, for moderate to severe adult AD patients (NCT04990440 and NCT04021862) were discontinued due to lack of efficacy, suggesting a limited role of IL-1α in human AD.